Pharsight

Drugs that contain Eluxadoline

1. Viberzi patents expiration

VIBERZI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8609709 ABBVIE Compounds as opioid receptor modulators
Mar, 2025

(9 months from now)

US10213415 ABBVIE Compounds as opioid receptor modulators
Mar, 2025

(9 months from now)

US7786158 ABBVIE Compounds as opioid receptor modulators
Mar, 2025

(9 months from now)

US9115091 ABBVIE Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Jul, 2028

(4 years from now)

US8691860 ABBVIE Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Jul, 2028

(4 years from now)

US7741356 ABBVIE Compounds as opioid receptor modulators
May, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9205076 ABBVIE Compounds as opioid receptor modulators
Mar, 2025

(9 months from now)

US9700542 ABBVIE Compounds as opioid receptor modulators
Mar, 2025

(9 months from now)

US8772325 ABBVIE Compounds as opioid receptor modulators
Mar, 2025

(9 months from now)

US8344011 ABBVIE Compounds as opioid receptor modulators
Mar, 2025

(9 months from now)

US9789125 ABBVIE Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Jul, 2028

(4 years from now)

US9364489 ABBVIE Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Jul, 2028

(4 years from now)

US11090291 ABBVIE Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US11484527 ABBVIE Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US9675587 ABBVIE Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US11007179 ABBVIE Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US11311516 ABBVIE Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US11229627 ABBVIE Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US10188632 ABBVIE Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US11160792 ABBVIE Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 27, 2020

NCE-1 date: 28 May, 2019

Market Authorisation Date: 27 May, 2015

Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).; Treatment of pain associated with irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline); Re...

Dosage: TABLET;ORAL

How can I launch a generic of VIBERZI before it's drug patent expiration?
More Information on Dosage

VIBERZI family patents

Family Patents